Type II cancers are clinically aggressive and comprise high-grade serous carcinoma (HG-SC), carcinosarcomas, and undifferentiated carcinomas, which are associated with mutations in TP53 and BRCA1/2 [4, 5]. Here, TP53 is linked to cancer.